Stemline’s aggressive haematological cancer therapy granted FDA orphan status 18 June 2013 / By Tim / Regulation & Government / 0 comments
Alexion’s late stage orphan drug granted “breakthrough drug” designation 18 June 2013 / By Tim / Regulation & Government / 0 comments
Verastem grab EU orphan drug designation for cancer stem cell therapy 13 June 2013 / By Tim / Regulation & Government / 0 comments
Is your #biotech candidate right for #orphandrug designation? #rarediseases 7 March 2012 / By Matt Turner / Uncategorized / 0 comments
Pharmaceutical Pricing & Reimbursement in Europe – Latest Report 12 January 2012 / By jane / Uncategorized / 0 comments
Report: The DNA of a #CFO by Ernst & Young #eynews 31 July 2011 / By Nicola Wartnaby / Uncategorized / 0 comments
